Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
accuracy, acetyl, Agennnix, Alemtuzumab, alkylating, apaziqone, arrest, Article, ASC, ASCNo, asEITF, ASP, auditor, backbone, ban, batch, belinostat, BiPar, borne, BR, break, budget, burden, catalyze, Celegen, Centered, cetrorelix, chimeric, CHOP, clarification, cleanup, clinician, Codification, CodificationTM, condensed, confidence, consecutive, consumption, copy, criterion, CRor, CUP, Dacetuzumab, deacetylase, deacytelase, debilitating, debiting, deducted, defensive, defict, delisted, delisting, Democratic, destruction, disaggregation, discarded, dispensing, display, dissimilar, distributor, document, donut, easier, EC, ECOG, eighteen, embedded, Endo, enterprise, environmental, enzymatically, Ernst, ESPP, essence, essential, EU, exciting, expediting, family, FCM, feature, freely, GA, Galizimab, gap, GELA, goodwill, handle, Handok, HDAC, Henderson, histone, hole, incorrectly, indoloquinone, inferior, intelligently, interchangeable, intermediate, invoice, IPRD, JDP, Korea, licensure, ligand, LLP, Lucatumumab, merged, MMA, mode, modular, motivated, nanotechnology, NCI, Nevada, newer, NOL, nonauthoritative, nonrecurring, Ofatumumab, ofRegulation, onASCNo, opposed, ordinarily, overcome, overseeing, owner, parallel, paramount, partnership, payer, persuasive, Pharm, pool, potent, PPACA, PR, preauthorization, predecessor, PRIMA, principle, privy, prompt, promptly, prong, prorated, provision, PTCL, publicationCancer, quantitative, radio, radiolabel, radiolabeled, radiolabeling, radiopharmacy, radiotherapeutic, rational, reaccorded, reassessed, reassessment, reauthorized, reauthorizing, reclassification, reclassified, reclassify, refund, regularly, Renalan, Renalin, reopen, Republic, requisite, resensitization, resold, restocking, retroactively, revaluation, revalued, reward, rollforward, satisfactory, sector, shipped, situation, solvency, sought, South, speak, strict, strive, sunset, SWOG, technical, theoretical, thousand, till, timeframe, top, Topic, topotarget, TPP, tradable, turnover, undiscounted, unfavorable, unqualified, variation, Veltuzumab, vessel, veterinarian, WAC, weakening, write, Young, ZevalinandFusilev
Removed:
abdominal, adrenergic, age, alpha, Amgen, amounted, approving, attestation, AVI, Bioniche, Biopharma, Black, block, cavity, certify, ciprofloxacin, clean, constructed, cure, derecognition, discomfort, dissolved, dosed, EITF, ejaculation, enlarged, enlargement, entry, extract, fainting, favor, FDIC, Ferring, fluconazole, foot, Frameworkissued, half, HDPC, Imitrex, impotence, incontinence, inInternal, injunction, intermittent, investable, JBCPL, justified, libido, likelihood, MAA, medicine, menopause, menstruating, moderate, MRP, NeoJB, nonvested, onset, optimistic, passing, Pharmion, predictable, progressing, prolonged, prostatic, PSA, rarely, receptor, reductase, refusal, relaxing, relief, renewal, reproductive, requiring, reversing, role, SAB, Score, showed, skilled, spearheaded, square, streamlined, supplied, suppression, Symptom, testosterone, transition, undergone, undertaken, upfront, urethra, vote, women
Filing tables
Filing exhibits
Related press release
SPPI similar filings
Filing view
External links
EXHIBIT 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference into the Company’s previously filed Registration Statements on Form S-3 (Nos. 333-163366, 333-150260, 333-142628, 333-135029, 333-125208, 333-121612, 333-115759, 333-110103, 333-108658, 333-105814, 333-102587, 333-64444, 333-64432, 333-60966, 333-51388, 333-42852, 333-38710, 333-37180, 333-92855, 333-73009, 333-52331, 333-37585) and Form S-8 (Nos. 333-160312, 333-160705, 333-164014, 333-134566, 333-119833, 333-106427, 333-54246, 333-30345), of our audit report on the consolidated financial statements dated March 31, 2009 and April 2, 2010 as it relates to Note 2, included in Spectrum Pharmaceuticals, Inc.’s Form 10-K for the year ended December 31, 2009.
/s/ Kelly & Company
Kelly & Company
Costa Mesa, California
April 2, 2010
Costa Mesa, California
April 2, 2010